Scantox A/S
CVR: 83090413
Secondary names: LAB RESEARCH DENMARK A/S, LAB SCANTOX A/S, SCANTOX BIOLOGISK LABORATORIUM A/S
Previous names: SCANTOX. BIOLOGISK LABORATORIUM A/S, LAB RESEARCH A/S, CITOXLAB SCANTOX A/S
Scantox A/S demonstrates a mixed financial health profile, with a notable decline in profitability from 2023 to 2024, where profit decreased from 17.3 million DKK to 9.6 million DKK despite a slight drop in revenue from 148 million DKK to 147 million DKK. The company has shown significant growth since 2020, recovering from a loss of 31 million DKK to achieving profits in subsequent years, indicating a positive trajectory overall. However, the equity position has weakened considerably, dropping from 42 million DKK in 2023 to 22.7 million DKK in 2024, raising concerns about financial stability. Positioned within the research and experimental development sector, Scantox A/S has established itself as a player, but its declining equity and profit margins warrant close monitoring.
AI-generated summary
Overview
Details
Contact
Purpose
Selskabets formål er at udføre farmakologiske og toksikologiske undersøgelser, biologiske styrkebestemmelser, biologiske kontrolundersøgelser og biologiske forskningsopgaver samt anden hermed beslægtet virksomhed.
Location
Financials
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 146.8 mio. | 9.6 mio. | 179.4 mio. | 22.7 mio. | 108 | |
History
Ownership
Properties
(3)3 properties
Upgrade to Pro to see addresses, building data and ownership details
Management
Directors
Board
Production units (3)
Similar companies
Companies in the same industry and area